DaVita (NYSE:DVA) Given New $215.00 Price Target at Truist Financial

DaVita (NYSE:DVA) had its price objective trimmed by Truist Financial from $250.00 to $215.00 in a report published on Friday, MarketBeat reports. The brokerage currently has a hold rating on the stock.

Several other research analysts have also commented on DVA. UBS Group upped their price objective on shares of DaVita from $235.00 to $270.00 and gave the stock a “buy” rating in a report on Friday, July 10th. Zacks Research cut shares of DaVita from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 6th. Oppenheimer set a $220.00 price target on shares of DaVita in a research note on Friday. Raymond James Financial set a $220.00 price objective on shares of DaVita in a report on Friday. Finally, Weiss Ratings upgraded DaVita from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday. Four analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $221.75.

DaVita Stock Performance

Shares of DVA stock opened at $183.39 on Friday. DaVita has a fifty-two week low of $101.00 and a fifty-two week high of $247.49. The firm has a market cap of $11.70 billion, a P/E ratio of 15.01, a P/E/G ratio of 0.60 and a beta of 0.88. The business’s 50 day moving average price is $218.43 and its 200-day moving average price is $176.53.

DaVita (NYSE:DVA) last announced its quarterly earnings results on Tuesday, August 4th. The company reported $4.02 EPS for the quarter, topping analysts’ consensus estimates of $3.88 by $0.14. The company had revenue of $3.55 billion during the quarter, compared to analyst estimates of $3.50 billion. DaVita had a negative return on equity of 217.63% and a net margin of 6.05%.The firm’s revenue was up 5.2% on a year-over-year basis. During the same quarter last year, the firm posted $2.95 earnings per share. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. As a group, equities analysts predict that DaVita will post 14.57 EPS for the current year.

Insider Buying and Selling at DaVita

In other news, insider Kathleen Alyce Waters sold 15,405 shares of the company’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $208.40, for a total value of $3,210,402.00. Following the sale, the insider directly owned 109,194 shares of the company’s stock, valued at $22,756,029.60. This represents a 12.36% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 1.90% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On DaVita

Hedge funds have recently bought and sold shares of the business. Value Investment Professionals LLC raised its position in DaVita by 2.0% during the second quarter. Value Investment Professionals LLC now owns 2,501 shares of the company’s stock valued at $556,000 after acquiring an additional 50 shares in the last quarter. Kesler Norman & Wride LLC boosted its position in DaVita by 0.8% in the 1st quarter. Kesler Norman & Wride LLC now owns 6,816 shares of the company’s stock worth $1,048,000 after purchasing an additional 55 shares in the last quarter. Gen Wealth Partners Inc grew its stake in shares of DaVita by 10.0% during the 4th quarter. Gen Wealth Partners Inc now owns 880 shares of the company’s stock worth $100,000 after purchasing an additional 80 shares during the period. NewEdge Advisors LLC increased its holdings in shares of DaVita by 20.8% during the 1st quarter. NewEdge Advisors LLC now owns 511 shares of the company’s stock valued at $78,000 after purchasing an additional 88 shares in the last quarter. Finally, Orion Porfolio Solutions LLC lifted its stake in shares of DaVita by 4.4% in the 4th quarter. Orion Porfolio Solutions LLC now owns 2,360 shares of the company’s stock valued at $268,000 after purchasing an additional 99 shares during the period. Institutional investors own 90.12% of the company’s stock.

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.